RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Number of tuberculosis patients in the Netherlands increased in 2023 compared to 2022 In 2023, 710 people in the Netherlands were diagnosed with tuberculosis (TB). This was 12 per cent more than in 2022, when there were 634. In 2023, 471 patients had pulmonary TB. Of these 417 patients, 213 had open TB – the most contagious type.
Cancer screening programmes now more accessible to transgender and intersex persons Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.
Tailor-made information will help immigrants make decisions on taking part in screening programmes Immigrants are relatively less likely to take part in preventive screening programmes, such as cancer screening. This is partly due to the language barrier and a lack of knowledge, according to a doctoral thesis by Nora Hamdiui.
Dutch collaboration in One Health European Joint Programme (EJP) RIVM, Wageningen Bioveterinary Research (WBVR) and the Netherlands Centre for One Health (NCOH) are involved in a recently granted One Health European Joint Programme which will start in January 20